Abstract
Several large-scale, double-blind, randomized, placebo-controlled clinical trials of the anti-immunoglobulin E (IgE) monoclonal antibody, rhuMAb-E25 (omalizumab) have demonstrated the benefits of this agent in patients with moderate to severe allergic asthma who remain symptomatic despite treatment with systemic or inhaled corticosteroids. The trials have consistently shown that administration of omalizumab is associated with fewer asthma exacerbations per patient despite significant reductions in corticosteroid dose, stable symptom control despite concomitant reductions in rescue medication use, and improvement in quality of life compared with placebo. In addition, anti-IgE (omalizumab) has been shown to be safe and well tolerated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Journal of Respiratory and Critical Care Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
